Zhonghua Klaus Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhonghua Klaus Chen has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Man Zhang
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Organ Transplantation Clinical Medical Research Center of Hubei Province Wuhan China
2 shared publicationsSheng Chang
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Organ Transplantation Clinical Medical Research Center of Hubei Province Wuhan China
2 shared publicationsB. Liu
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, and Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China
1 shared publicationBing Li
The Second Affiliated Hospital and the Transplantation Institute, Hainan Medical University, Hainan, China
1 shared publicationChangsheng Ming
Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University), Taiyuan, China
1 shared publicationDengke Pan
Chengdu Clonorgan Biotechnology Co., LTD, Chengdu, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 12 February 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 92
Global inequities in organ transplantation, 2008–2023: trends, unmet need, and policy implications
- 12 February 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 92
Top Cited PapersOpen AccessGlobal inequities in organ transplantation, 2008–2023: trends, unmet need, and policy implications
- Open Access
- 8 December 2025
- Published by Wiley in Immunology
- Vol. 177 (4) , 752-765
Interferon Regulatory Factor 2 ( IRF2 ) Suppression Enhances Murine Cardiac Allograft Survival Through Immune Evasion
Transplant rejection, primarily caused by the immune system's recognition of allografts, continues to pose a significant challenge to graft survival. Drawing inspiration from the function of interferon regulatory factor 2 (IRF2) in tumour immune evasion, we explored its potential role in the context of transplantation. We quantified the expression of MHC‐I, PD‐L1 and associated molecules in cardiac tissues of IRF2 KO mice through RNA and protein analyses. Subsequently, we established a murine heterotopic cardiac transplantation model using IRF2‐KO donors to evaluate the role of IRF2 in post‐transplant survival. Immunofluorescence and immunohistochemical staining revealed IRF2‐dependent regulation of MHC‐I and PD‐L1 in grafts, accompanied by altered CD4 + /CD8 + T‐cell infiltration patterns. Further, in vitro experiments employing RNA interference (RNAi) in cardiomyocytes demonstrated IRF2‐mediated control of MHC‐I/PD‐L1 expression and its functional impact on T‐cell proliferation and apoptosis in co‐culture systems. In mice heart tissues, as revealed by the transcriptome sequencing, IRF2 knockdown downregulated immune‐related pathways (MHC, inflammation) and upregulated apoptosis‐linked pathways. IRF2 deficiency enhances PD‐L1 and suppresses TAP2/ERAP1‐MHC‐I axis at RNA and protein levels. After transplantation, IRF2 deficiency in allografts prolongs survival by attenuating CD4 + /CD8 + T‐cell infiltration via PD‐L1 upregulation and MHC‐I downregulation, thereby mitigating inflammatory injury. In vitro, IRF2 knockdown in HL‐1 murine cardiomyocytes via siRNA upregulated PD‐L1 expression, suppressed TAP2/ERAP1 levels and attenuated T‐cell proliferation while promoting apoptosis in co‐culture systems. We elucidate the principal mechanism underlying IRF2‐mediated allograft immune evasion, thereby identifying its targeted modulation as an innovative therapeutic approach to prevent early acute rejection and diminish long‐term reliance on immunosuppressive therapy in transplantation.
- 8 December 2025
- Published by Wiley in Immunology
- Vol. 177 (4) , 752-765
Open AccessInterferon Regulatory Factor 2 ( IRF2 ) Suppression Enhances Murine Cardiac Allograft Survival Through Immune Evasion
Transplant rejection, primarily caused by the immune system's recognition of allografts, continues to pose a significant challenge to graft survival. Drawing inspiration from the function of interferon regulatory factor 2 (IRF2) in tumour immune evasion, we explored its potential role in the context of transplantation. We quantified the expression of MHC‐I, PD‐L1 and associated molecules in cardiac tissues of IRF2 KO mice through RNA and protein analyses. Subsequently, we established a murine heterotopic cardiac transplantation model using IRF2‐KO donors to evaluate the role of IRF2 in post‐transplant survival. Immunofluorescence and immunohistochemical staining revealed IRF2‐dependent regulation of MHC‐I and PD‐L1 in grafts, accompanied by altered CD4 + /CD8 + T‐cell infiltration patterns. Further, in vitro experiments employing RNA interference (RNAi) in cardiomyocytes demonstrated IRF2‐mediated control of MHC‐I/PD‐L1 expression and its functional impact on T‐cell proliferation and apoptosis in co‐culture systems. In mice heart tissues, as revealed by the transcriptome sequencing, IRF2 knockdown downregulated immune‐related pathways (MHC, inflammation) and upregulated apoptosis‐linked pathways. IRF2 deficiency enhances PD‐L1 and suppresses TAP2/ERAP1‐MHC‐I axis at RNA and protein levels. After transplantation, IRF2 deficiency in allografts prolongs survival by attenuating CD4 + /CD8 + T‐cell infiltration via PD‐L1 upregulation and MHC‐I downregulation, thereby mitigating inflammatory injury. In vitro, IRF2 knockdown in HL‐1 murine cardiomyocytes via siRNA upregulated PD‐L1 expression, suppressed TAP2/ERAP1 levels and attenuated T‐cell proliferation while promoting apoptosis in co‐culture systems. We elucidate the principal mechanism underlying IRF2‐mediated allograft immune evasion, thereby identifying its targeted modulation as an innovative therapeutic approach to prevent early acute rejection and diminish long‐term reliance on immunosuppressive therapy in transplantation.
- Top Cited PapersOpen Access
- 23 September 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (10) , 101744
Pig-to-human kidney xenotransplants using genetically modified minipigs
- 23 September 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (10) , 101744
Top Cited PapersOpen AccessPig-to-human kidney xenotransplants using genetically modified minipigs
- Open Access
- 5 February 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (2) , 456-458
A Case Report of Modified Pancreatic Transplantation With a Limited Splenic Arteriovenous Fistula to Elude Thrombosis
- 5 February 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (2) , 456-458
Open AccessA Case Report of Modified Pancreatic Transplantation With a Limited Splenic Arteriovenous Fistula to Elude Thrombosis
- Open Access
- 24 June 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 1326
Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies
Liver transplantation is currently the most effective method for treating end-stage liver disease. However, recipients still need long-term immunosuppressive drug treatment to control allogeneic immune rejection, which may cause various complications and affect the long-term survival of the recipient. Many liver transplant researchers constantly pursue the induction of immune tolerance in liver transplant recipients, immunosuppression withdrawal, and the maintenance of good and stable graft function. Although allogeneic liver transplantation is more tolerated than transplantation of other solid organs, and it shows a certain incidence of spontaneous tolerance, there is still great risk for general recipients. With the gradual progress in our understanding of immune regulatory mechanisms, a variety of immune regulatory cells have been discovered, and good results have been obtained in rodent and non-human primate transplant models. As immune cell therapies can induce long-term stable tolerance, they provide a good prospect for the induction of tolerance in clinical liver transplantation. At present, many transplant centers have carried out tolerance-inducing clinical trials in liver transplant recipients, and some have achieved gratifying results. This article will review the current status of liver transplant tolerance and the research progress of different cellular immunotherapies to induce this tolerance, which can provide more support for future clinical applications.
- 24 June 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 1326
Open AccessProgress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies
Liver transplantation is currently the most effective method for treating end-stage liver disease. However, recipients still need long-term immunosuppressive drug treatment to control allogeneic immune rejection, which may cause various complications and affect the long-term survival of the recipient. Many liver transplant researchers constantly pursue the induction of immune tolerance in liver transplant recipients, immunosuppression withdrawal, and the maintenance of good and stable graft function. Although allogeneic liver transplantation is more tolerated than transplantation of other solid organs, and it shows a certain incidence of spontaneous tolerance, there is still great risk for general recipients. With the gradual progress in our understanding of immune regulatory mechanisms, a variety of immune regulatory cells have been discovered, and good results have been obtained in rodent and non-human primate transplant models. As immune cell therapies can induce long-term stable tolerance, they provide a good prospect for the induction of tolerance in clinical liver transplantation. At present, many transplant centers have carried out tolerance-inducing clinical trials in liver transplant recipients, and some have achieved gratifying results. This article will review the current status of liver transplant tolerance and the research progress of different cellular immunotherapies to induce this tolerance, which can provide more support for future clinical applications.
- 1 December 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (10) , 3314-3320
Accumulation of High Levels of Monocytic Myeloid-Derived Suppressor Cells Enhances Graft Survival in Almost-Tolerant Kidney Transplant Recipients
- 1 December 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (10) , 3314-3320
Accumulation of High Levels of Monocytic Myeloid-Derived Suppressor Cells Enhances Graft Survival in Almost-Tolerant Kidney Transplant Recipients